Information for Patients:

Neurologic Adverse Reactions

The following may be symptoms of ICANS:

- Confusion
- Difficulty with memory
- Difficulty speaking or slowed speech
- Difficulty understanding speech
- Loss of balance or coordination
- Disorientation
- Being less alert (decreased consciousness) or excessive sleepiness
- Loss of consciousness
- Delirious
- Fits (seizures)

Also, shaking, weakness with loss of movement on one side of the body, tremor, slow movements, or stiffness, which may be symptoms of parkinsonism.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com

Date of preparation: Oct 2024
Approved by MHRA: Nov 2024
2012-GB-2400017

ABECMA® ▼
(idecabtagene vicleucel)
Patient Card

UK Version 2.0

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Have this card with you at all times. Show it to any doctor/healthcare provider who sees you, including in conditions of emergency.

- Tell any healthcare provider who sees you that you are being treated with idecabtagene vicleucel.
- For at least 4 weeks after receiving idecabtagene vicleucel, you should plan to stay close (within 2 hours of travel) to the location where you received treatment.

Bristol Myers Squibb®

Date of preparation: Oct 2024
Approved by MHRA: Nov 2024
2012-GB-2400017

I have been treated with idecabtagene vicleucel

Important Contact Information

My Name (PRINT): _____

Name of idecabtagene vicleucel Treating Physician (PRINT): _____

Office/Hospital Phone Number: _____

After-hours Phone Number: _____

Hospital Name: _____

Date of idecabtagene vicleucel Infusion (DD/MM/YYYY): _____

Lot Number (PRINT): _____

Information for the Healthcare Provider:

This patient has received idecabtagene vicleucel CAR T cell therapy, a B-cell maturation antigen (BCMA) directed genetically modified autologous T cell immunotherapy.

Following treatment with idecabtagene vicleucel, cytokine release syndrome (CRS) and/or neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), may occur, which may be fatal or life threatening. CRS may involve any organ system.

Contact patient's idecabtagene vicleucel treating physician immediately for further information.

Please see idecabtagene vicleucel's Summary of Product Characteristics and Package Leaflet, which can be found at www.medicines.org.uk/emc.

Information for Patients:

Idecabtagene vicleucel may cause side effects that are severe or life-threatening. **Call your idecabtagene vicleucel treating physician or go to the accident & emergency department immediately if any of the following signs or symptoms appear:**

Cytokine Release Syndrome (CRS)

- Fever
- Chills
- Difficulty breathing
- Low blood pressure
- Dizziness or light-headedness
- Nausea
- Headache
- Fast heartbeat
- Fatigue